[
  {
    "ts": null,
    "headline": "Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown",
    "summary": "Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges like PET scan reimbursement, slow protocol updates at major hospital networks, and identifying eligible patients continue to hinder adoption. The analyst sees limited downside at current valuations and notes that continued pipeline progress, regulatory approvals, and a successful lecanemab launch could pus",
    "url": "https://finnhub.io/api/news?id=19605ef572d7bd5fb594531b7b72ef5a065b75540e57d354445c2e8a9497eda5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733769853,
      "headline": "Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown",
      "id": 131894001,
      "image": "https://media.zenfs.com/en/Benzinga/7ebf94f4bb8b321649be7ef19d065ecf",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges like PET scan reimbursement, slow protocol updates at major hospital networks, and identifying eligible patients continue to hinder adoption. The analyst sees limited downside at current valuations and notes that continued pipeline progress, regulatory approvals, and a successful lecanemab launch could pus",
      "url": "https://finnhub.io/api/news?id=19605ef572d7bd5fb594531b7b72ef5a065b75540e57d354445c2e8a9497eda5"
    }
  },
  {
    "ts": null,
    "headline": "Biogen cut at Jefferies as '2025 has a tough setup'",
    "summary": "Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025.  Analysts highlighted that Biogen’s Alzheimer's drug, Leqembi, faces slower-than-expected growth, with Jefferies lowering its 2025 sales estimates to $466 million, below the consensus of $494 million.  “We move to HOLD as 2025 has a tough setup: modest Leqembi (we're below consensus) and Skyclarys US (mostly penetrated), and real need for more pipeline and serious BD to get investors re-engaged,” said Jefferies.",
    "url": "https://finnhub.io/api/news?id=245f05912baf343ae89be4f6979a6c65e20a420a50985078767169616efdb78b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733765221,
      "headline": "Biogen cut at Jefferies as '2025 has a tough setup'",
      "id": 131894004,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025.  Analysts highlighted that Biogen’s Alzheimer's drug, Leqembi, faces slower-than-expected growth, with Jefferies lowering its 2025 sales estimates to $466 million, below the consensus of $494 million.  “We move to HOLD as 2025 has a tough setup: modest Leqembi (we're below consensus) and Skyclarys US (mostly penetrated), and real need for more pipeline and serious BD to get investors re-engaged,” said Jefferies.",
      "url": "https://finnhub.io/api/news?id=245f05912baf343ae89be4f6979a6c65e20a420a50985078767169616efdb78b"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=6a8dc286545d7eae0f5de3303d009315085eb7f87419295f9d40679569a0fc76",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733764020,
      "headline": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "id": 131888417,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=6a8dc286545d7eae0f5de3303d009315085eb7f87419295f9d40679569a0fc76"
    }
  },
  {
    "ts": null,
    "headline": "Tax-Loss Stocks To Sell Before Everyone Else Does",
    "summary": "Prepare for tax-loss selling at year-end by considering selling underperforming stocks like Celanese, Walgreens, and Intel. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=f1721d0d8f7ac3f6583890510ac501d4aeac1ccc40598c7bb3e71a898eb673eb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733735024,
      "headline": "Tax-Loss Stocks To Sell Before Everyone Else Does",
      "id": 131869198,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1795167728/image_1795167728.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Prepare for tax-loss selling at year-end by considering selling underperforming stocks like Celanese, Walgreens, and Intel. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=f1721d0d8f7ac3f6583890510ac501d4aeac1ccc40598c7bb3e71a898eb673eb"
    }
  },
  {
    "ts": null,
    "headline": "Biogen : Appoints Tim Power as Head of Investor Relations",
    "summary": "today announced the appointment of Tim Power as Vice President, Head of Investor Relations, effective December 9, 2024. Mr. Power will report to Michael McDonnell, Executive Vice President and Chief...",
    "url": "https://finnhub.io/api/news?id=aa477e1a92f3b8d17cde0294cbd5ef6e29af7cb60df81d9ccf39ecaaf319b849",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733730245,
      "headline": "Biogen : Appoints Tim Power as Head of Investor Relations",
      "id": 131868179,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "today announced the appointment of Tim Power as Vice President, Head of Investor Relations, effective December 9, 2024. Mr. Power will report to Michael McDonnell, Executive Vice President and Chief...",
      "url": "https://finnhub.io/api/news?id=aa477e1a92f3b8d17cde0294cbd5ef6e29af7cb60df81d9ccf39ecaaf319b849"
    }
  }
]